Completeness in the Reporting of Dermatologic Adverse Drug Reactions Associated with Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors in Phase II and III Colorectal Cancer Clinical Trials

The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis

“…We believe this is due to the issue of under-reporting or inconsistent reporting of nail changes, as has been shown with rash. 48 The diagnosis may be difficult due to many causes, including the slow growth rate of nails, the abnormalities may not involve all nails, a poor understanding of the pathogenesis of nail damage, as well as there being few histological specimens available for analysis. 49,50 No trials that fit our study selection criteria were found for lapatinib as well.…”

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

“…Improved and consistent reporting of toxicities is essential for evaluation of their impact and would allow for inter-agent toxicity profile comparisons. 100 In addition, efforts should be directed at detecting potential risk factors and development of prediction models to identify patients at high risk. The emerging field of supportive oncodermatology will serve as a basis for accomplishing these goals, raising awareness of dermatologic toxicities and optimizing the dermatology-related QoL in cancer patients, all of which would maximize anticancer regimens.…”

Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review

“…Subsequently, introduction of irinotecan and oxaliplatin gave additional first-line therapy choices. [12] More recently, it has been estimated that between 60% and 80% of CRCs over-express EGFR, which may be also associated with an advanced disease stage. This discovery has resulted in the development and use of EGFRIs in CRC.…”